Viloxazine Disease Interactions

All antidepressants may occasionally cause mania or hypomania, particularly in patients with bipolar disorder. Therapy with antidepressants should be administered cautiously in patients with a history of mania/hypomania.

Patients being treated with viloxazine should be monitored for clinical worsening and emergence of suicidal thoughts and behaviors. In clinical trials, higher rates of suicidal thoughts and behavior were reported in pediatric patients with attention deficit hyperactivity disorder (ADHD) receiving this drug than placebo. Prior to initiating treatment, patients should be screened for a personal or family history of suicide, bipolar disorder, and depression.

The effect of hepatic impairment on the pharmacokinetics of viloxazine is unknown. Viloxazine is not recommended in patients with hepatic impairment.

The exposure of viloxazine increases in patients with renal impairment. Dose reduction is recommended in patients with severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m3).